Last 12 months
Inside the activity.
0 purchase rows · 6 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2022 Filed Mar 1, 2022 23:09 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
SaleCommon Stock, $0.01 par value | 14,424 | $148.59 | $2,143,195.81 |
DisclosureSEC source: 0001179110-22-001834 · edgar.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,464 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.91 to $148.90 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:09 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
SaleCommon Stock, $0.01 par value | 9,381 | $147.52 | $1,383,917.95 |
DisclosureSEC source: 0001179110-22-001834 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,888 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.89 to $147.88 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:11 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
SaleCommon Stock, $0.01 par value | 700 | $149.07 | $104,351.03 |
DisclosureSEC source: 0001179110-22-001837 · edgar.xml · nonDerivative · entry 4 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,876 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.93 to $149.38 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:11 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
SaleCommon Stock, $0.01 par value | 3,451 | $148.59 | $512,783.05 |
DisclosureSEC source: 0001179110-22-001837 · edgar.xml · nonDerivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,576 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.93 to $148.91 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:11 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
SaleCommon Stock, $0.01 par value | 2,333 | $147.59 | $344,332.60 |
DisclosureSEC source: 0001179110-22-001837 · edgar.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,027 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.93 to $147.88 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:14 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
SaleCommon Stock, $0.01 par value | 1,101 | $149.14 | $164,207.65 |
DisclosureSEC source: 0001179110-22-001841 · edgar.xml · nonDerivative · entry 4 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,623 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.95 to $149.40 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:14 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
SaleCommon Stock, $0.01 par value | 8,303 | $148.62 | $1,234,011.79 |
DisclosureSEC source: 0001179110-22-001841 · edgar.xml · nonDerivative · entry 3 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,724 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.94 to $148.93 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:14 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
SaleCommon Stock, $0.01 par value | 5,596 | $147.54 | $825,616.49 |
DisclosureSEC source: 0001179110-22-001841 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,027 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.89 to $147.88 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 22:03 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
SaleCommon Stock, $0.01 par value | 100 | $149.38 | $14,938.10 |
DisclosureSEC source: 0001179110-22-001923 · edgar.xml · nonDerivative · entry 4 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,623 F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.38 to $149.39 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 22:03 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
SaleCommon Stock, $0.01 par value | 4,000 | $148.71 | $594,824.00 |
DisclosureSEC source: 0001179110-22-001923 · edgar.xml · nonDerivative · entry 3 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,723 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.37 to $148.96 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 22:03 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
SaleCommon Stock, $0.01 par value | 5,167 | $147.60 | $762,656.95 |
DisclosureSEC source: 0001179110-22-001923 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,723 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.35 to $148.11 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 22:03 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
SaleCommon Stock, $0.01 par value | 15,733 | $146.81 | $2,309,769.60 |
DisclosureSEC source: 0001179110-22-001923 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,890 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.31 to $147.30 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed May 20, 2022 21:00 UTC Amendment |
Gosebruch Henry OEVP, Chief Strategy Officer
|
SaleCommon Stock, $0.01 par value | 100 | $149.38 | $14,938.10 |
DisclosureSEC source: 0001179110-22-003107 · edgar.xml · nonDerivative · entry 5 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Indirect · In trust Disclosed balance after: 53,500 F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.38 to $149.39 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · balance_after: The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust. F7 · balance_after: Due to an administrative error, the original Form 4 filed on March 2, 2022 incorrectly reported that the 25,000 securities sold on March 1, 2022 were securities directly owned by the reporting person. Instead, the securities sold on that date were securities indirectly owned in trust by the reporting person. This amended Form 4 corrects that error. Read SEC document |
| March 01, 2022 Filed May 20, 2022 21:00 UTC Amendment |
Gosebruch Henry OEVP, Chief Strategy Officer
|
SaleCommon Stock, $0.01 par value | 4,000 | $148.71 | $594,824.00 |
DisclosureSEC source: 0001179110-22-003107 · edgar.xml · nonDerivative · entry 4 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Indirect · In trust Disclosed balance after: 53,600 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.37 to $148.96 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed May 20, 2022 21:00 UTC Amendment |
Gosebruch Henry OEVP, Chief Strategy Officer
|
SaleCommon Stock, $0.01 par value | 5,167 | $147.60 | $762,656.95 |
DisclosureSEC source: 0001179110-22-003107 · edgar.xml · nonDerivative · entry 3 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Indirect · In trust Disclosed balance after: 57,600 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.35 to $148.11 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed May 20, 2022 21:00 UTC Amendment |
Gosebruch Henry OEVP, Chief Strategy Officer
|
SaleCommon Stock, $0.01 par value | 15,733 | $146.81 | $2,309,769.60 |
DisclosureSEC source: 0001179110-22-003107 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Indirect · In trust Disclosed balance after: 62,767 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.31 to $147.30 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 18:06 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Tax withholdingCommon Stock, $0.01 par value | 102,812 | $149.54 | $15,374,506.48 |
DisclosureSEC source: 0001179110-22-001825 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,253 Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:06 UTC |
Schumacher Laura JVice Chairman
|
Tax withholdingCommon Stock, $0.01 par value | 40,490 | $149.54 | $6,054,874.60 |
DisclosureSEC source: 0001179110-22-001826 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,002 Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 18:07 UTC |
Michael Robert A.Vice Chairman
|
Tax withholdingCommon Stock, $0.01 par value | 34,286 | $149.54 | $5,127,128.44 |
DisclosureSEC source: 0001179110-22-001828 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,982 Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:08 UTC |
SEVERINO MICHAELVice Chairman
|
Tax withholdingCommon Stock, $0.01 par value | 38,857 | $149.54 | $5,810,675.78 |
DisclosureSEC source: 0001179110-22-001829 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,103 Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:08 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
Tax withholdingCommon Stock, $0.01 par value | 22,108 | $149.54 | $3,306,030.32 |
DisclosureSEC source: 0001179110-22-001830 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,912 Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:08 UTC |
Stewart Jeffrey RyanEVP, Chief Commercial Officer
|
Tax withholdingCommon Stock, $0.01 par value | 17,093 | $149.54 | $2,556,087.22 |
DisclosureSEC source: 0001179110-22-001832 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,429 Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:09 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
Tax withholdingCommon Stock, $0.01 par value | 21,027 | $149.54 | $3,144,377.58 |
DisclosureSEC source: 0001179110-22-001834 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,269 Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:09 UTC |
Hudson Thomas JSVP, R&D and CSO
|
Tax withholdingCommon Stock, $0.01 par value | 13,408 | $149.54 | $2,005,032.32 |
DisclosureSEC source: 0001179110-22-001835 · edgar.xml · nonDerivative · entry 1 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,228 Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:11 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
Tax withholdingCommon Stock, $0.01 par value | 11,125 | $149.54 | $1,663,632.50 |
DisclosureSEC source: 0001179110-22-001837 · edgar.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,360 Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:11 UTC |
Durkin Brian LVP, Controller
|
Tax withholdingCommon Stock, $0.01 par value | 7,589 | $149.54 | $1,134,859.06 |
DisclosureSEC source: 0001179110-22-001839 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,040 Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:14 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
Tax withholdingCommon Stock, $0.01 par value | 30,156 | $149.54 | $4,509,528.24 |
DisclosureSEC source: 0001179110-22-001841 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,623 Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:15 UTC |
Strom Carrie CSVP & Pres Global Allerg Aesth
|
Tax withholdingCommon Stock, $0.01 par value | 2,840 | $149.54 | $424,693.60 |
DisclosureSEC source: 0001179110-22-001842 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,386 Read SEC document |
| February 24, 2022 Filed Mar 1, 2022 18:06 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GiftCommon Stock, $0.01 par value | 2,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001825 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606,065 Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 17:32 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantOption (Right To Buy) · Derivative | 157,618 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001506 · edgar.xml · derivative · entry 8 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,618 Underlying: Common Stock · 157,618 shares Expires 2032-02-16 F6 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 52,540 on February 17, 2023, 52,539 on February 17, 2024, and 52,539 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 17:32 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantCommon Stock, $0.01 par value | 34,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001506 · edgar.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,675 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 17:32 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantCommon Stock, $0.01 par value | 34,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001506 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 574,529 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 17:32 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantCommon Stock, $0.01 par value | 29,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001506 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,592 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 17:32 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantCommon Stock, $0.01 par value | 133,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001506 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,486 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:32 UTC |
SEVERINO MICHAELVice Chairman
|
GrantOption (Right to Buy) · Derivative | 48,161 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001507 · edgar.xml · derivative · entry 5 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,161 Underlying: Common Stock · 48,161 shares Expires 2032-02-16 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,054 on February 17, 2023, 16,054 on February 17, 2024, and 16,053 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:32 UTC |
SEVERINO MICHAELVice Chairman
|
GrantCommon Stock, $0.01 par value | 11,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001507 · edgar.xml · nonDerivative · entry 4 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,960 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:32 UTC |
SEVERINO MICHAELVice Chairman
|
GrantCommon Stock, $0.01 par value | 17,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001507 · edgar.xml · nonDerivative · entry 3 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,395 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:32 UTC |
SEVERINO MICHAELVice Chairman
|
GrantCommon Stock, $0.01 par value | 10,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001507 · edgar.xml · nonDerivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,927 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:32 UTC |
SEVERINO MICHAELVice Chairman
|
GrantCommon Stock, $0.01 par value | 48,198 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001507 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,450 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:33 UTC |
Schumacher Laura JVice Chairman
|
GrantOption (Right to Buy) · Derivative | 56,917 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001508 · edgar.xml · derivative · entry 5 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,917 Underlying: Common Stock · 56,917 shares Expires 2032-02-16 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,973 on February 17, 2023, 18,972 on February 17, 2024, and 18,972 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:33 UTC |
Schumacher Laura JVice Chairman
|
GrantCommon Stock, $0.01 par value | 11,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001508 · edgar.xml · nonDerivative · entry 4 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,492 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:33 UTC |
Schumacher Laura JVice Chairman
|
GrantCommon Stock, $0.01 par value | 17,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001508 · edgar.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,927 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:33 UTC |
Schumacher Laura JVice Chairman
|
GrantCommon Stock, $0.01 par value | 11,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001508 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,459 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:33 UTC |
Schumacher Laura JVice Chairman
|
GrantCommon Stock, $0.01 par value | 51,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001508 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,323 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:33 UTC |
Hudson Thomas JSVP, R&D and CSO
|
GrantOption (Right to Buy) · Derivative | 25,394 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001509 · edgar.xml · derivative · entry 5 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,394 Underlying: Common Stock · 25,394 shares Expires 2032-02-16 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,465 on February 17, 2023, 8,465 on February 17, 2024, and 8,465 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:33 UTC |
Hudson Thomas JSVP, R&D and CSO
|
GrantCommon Stock, $0.01 par value | 6,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001509 · edgar.xml · nonDerivative · entry 4 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,636 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:33 UTC |
Hudson Thomas JSVP, R&D and CSO
|
GrantCommon Stock, $0.01 par value | 9,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001509 · edgar.xml · nonDerivative · entry 3 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,027 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:33 UTC |
Hudson Thomas JSVP, R&D and CSO
|
GrantCommon Stock, $0.01 par value | 2,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001509 · edgar.xml · nonDerivative · entry 2 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,544 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:33 UTC |
Hudson Thomas JSVP, R&D and CSO
|
GrantCommon Stock, $0.01 par value | 11,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001509 · edgar.xml · nonDerivative · entry 1 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,014 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:34 UTC |
Durkin Brian LVP, Controller
|
GrantOption (Right to Buy) · Derivative | 10,945 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001510 · edgar.xml · derivative · entry 5 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,945 Underlying: Common Stock · 10,945 shares Expires 2032-02-16 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,649 on February 17, 2023, 3,648 on February 17, 2024, and 3,648 on February 17, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.